Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATPCI study of trimetazidine after PCI in angina patients
NL-OMON38975Phase 3Withdrawn
- Sponsor
- Servier
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of trimetazidine in angina pectoris and coronary arteriosclerosis, sponsored by Servier. Primary endpoint: Primary composite time-to-first-event endpoint. Planned start Oct 2013; status: withdrawn.
02
Drugs
trimetazidine
03
Conditions
angina pectoriscoronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON38975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38975.